Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate \[Ca-EDTA\] and dimercaptosuccinic acid \[DMSA\]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found in the blood/bone marrow may help to control the disease and/or improve the response to chemotherapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Nowo rozpoznana białaczka ostra lub podobne nowotwory szpiku kostnego średniego lub wysokiego ryzyka
- •Wtórna białaczka ostra (rozwinęła się z innej choroby krwi)
- •Rozpoczęcie leczenia nie później niż w drugiej serii terapii
- •Dobry ogólny stan zdrowia (ocena ECOG 0-2)
✗ Disqualifies
- •Osoby poniżej 18 lat
- •Białaczka ostra całkowicie wyleczona (w pełnej remisji)
- •Pewne rzadkie podtypy białaczki ostrej (z translokacją t(8;21) lub inv(16))
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
The University of Texas M. D. Anderson Cancer Center
Houston, United States
Trial contact
Maro Ohanian, DO
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.